Bastien’s Mother Pleads for Treatment
- DOL-DE-BRETAGNE, France (May 12, 2025) — A 10-year-old boy in Dol-de-Bretagne, identified as Bastien, is no longer able to receive a medication his parents credit with slowing the...
- Bastien has suffered from Duchenne myopathy,a rare genetic disorder characterized by progressive muscle degeneration,since he was 18 months old.
- The EMA's decision has been met with dismay by Bastien's family."These sachets bring my son to life," said Caroline, Bastien's mother, who works as a gendarme in Ille-et-Vilaine.
French Boy, 10, Loses Access to myopathy Drug After European Agency Ruling
Table of Contents
- French Boy, 10, Loses Access to myopathy Drug After European Agency Ruling
- French Boy’s fight for Myopathy Drug: A Q&A Guide
- What happened to Bastien, the 10-year-old French boy?
- What disease does Bastien have?
- What drug was Bastien taking, and why was it stopped?
- How has the EMA’s decision affected Bastien’s family?
- What are the immediate consequences of Bastien no longer receiving this medication?
- What efforts are being made to help Bastien?
- Is Bastien’s case unique?
- What are the wider implications of the EMA’s decision?
- Can you provide a summary of the key facts?
DOL-DE-BRETAGNE, France (May 12, 2025) — A 10-year-old boy in Dol-de-Bretagne, identified as Bastien, is no longer able to receive a medication his parents credit with slowing the progression of his incurable disease, following a decision by the European Medicines Agency.
Duchenne Myopathy Treatment Halted
Bastien has suffered from Duchenne myopathy,a rare genetic disorder characterized by progressive muscle degeneration,since he was 18 months old. until recently, a drug called Translarna was used to mitigate the disease’s effects. However, at the end of April, the European medicines Agency (EMA) suspended the drug’s marketing authorization, citing inconclusive evidence of its effectiveness.
Family Devastated by Decision
The EMA’s decision has been met with dismay by Bastien’s family.”These sachets bring my son to life,” said Caroline, Bastien’s mother, who works as a gendarme in Ille-et-Vilaine. According to Caroline, Bastien asked her, “Will I die?” after learning he could no longer receive the medication.
Impact of Treatment Cessation
In the absence of the treatment, Bastien’s parents have attempted to ration the remaining doses, administering them every other day. The effects of this reduction are already apparent,with Bastien experiencing increased fatigue,frequent falls,and heightened pain levels. “we had a sword of Damocles. Now she borders on our throat,” Caroline said.
Advocacy Efforts Underway
AFM-Téléthon, a French organization dedicated to fighting genetic diseases, has appealed to the Ministry of Health to grant an remarkable extension for patients who have demonstrably benefited from the drug. denis Rapinel, the mayor of Dol-de-Bretagne, has also voiced his support for the family, questioning the rationale behind removing a treatment that appears to be helping a child.
Wider Implications
Bastien’s case is not isolated. According to Caroline, two other children in western France are affected by the EMA’s decision. She remains steadfast in her determination to fight for her son’s access to the medication. “Even if it’s one in ten, why take her chance to her?” she said.
French Boy’s fight for Myopathy Drug: A Q&A Guide
What happened to Bastien, the 10-year-old French boy?
Bastien, a 10-year-old boy from Dol-de-Bretagne, France, is no longer able to receive a medication that his parents believe slows the progression of his incurable disease. This is due to a decision made by the European Medicines Agency (EMA). The article mentions that the event occured in May 2025.
What disease does Bastien have?
Bastien suffers from Duchenne myopathy. This is a rare genetic disorder characterized by progressive muscle degeneration. He has been diagnosed with this condition since he was 18 months old.
What drug was Bastien taking, and why was it stopped?
Bastien was being treated with a drug called Translarna to mitigate the effects of Duchenne myopathy. However, the EMA suspended the drug’s marketing authorization at the end of April based on inconclusive evidence of its effectiveness.Therefore, he can no longer access this treatment.
How has the EMA’s decision affected Bastien’s family?
The EMA’s decision has been met with dismay by Bastien’s family. His mother, Caroline, stated that the medication “bring[s] my son to life.” She describes how Bastien asked her after learning he could no longer receive the drug,”Will I die?”
What are the immediate consequences of Bastien no longer receiving this medication?
In the absence of the treatment,Bastien’s parents have been rationing the remaining doses. They administer the medication every other day. The effects of this reduction have become apparent: Bastien is experiencing increased fatigue, frequent falls, and heightened pain levels.
What efforts are being made to help Bastien?
AFM-Téléthon, a French institution dedicated to fighting genetic diseases, has appealed to the Ministry of Health to grant an extension for patients who have clearly benefited from the drug.Also, Denis Rapinel, the mayor of Dol-de-Bretagne, is supporting the family.
Is Bastien’s case unique?
No, Bastien’s case is not isolated. According to Caroline, two other children in western France are affected by the EMA’s decision.
What are the wider implications of the EMA’s decision?
The situation highlights the challenges faced by families dealing with rare diseases and the potential impact of decisions made by regulatory bodies. The article emphasizes that the mother, Caroline, is determined to fight for her son’s access to the medication. She states, “Even if it’s one in ten, why take her chance to her?”
Can you provide a summary of the key facts?
Absolutely. Here’s a summary in an HTML table:
| Aspect | Details |
|---|---|
| Patient | Bastien, 10-year-old boy from France |
| Disease | Duchenne myopathy (a rare genetic muscle disorder) |
| Previous Treatment | Translarna (drug intended to mitigate disease effects) |
| Reason for Treatment Change | EMA suspended marketing authorization due to inconclusive effectiveness evidence |
| Family’s Reaction | Dismay and fear of the drug’s cessation. |
| Current Situation | Treatment cessation has led to rationed doses and worsening symptoms |
| Advocacy | AFM-Téléthon and local Mayor are providing supportive resources |
| Wider Impact | Similar issues are affecting at least two other children in western France |